




















# Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Meletios A. Dimopoulos, MD<sup>1</sup> ; Stephen Opat, MBBS<sup>2</sup> ; Shirley D'Sa, MD<sup>3</sup>; Wojciech Jurczak, MD<sup>4</sup>; Hui-Peng Lee, MBChB<sup>5</sup>; Gavin Cull, MBBS<sup>6</sup>; Roger G. Owen, MD<sup>7</sup>; Paula Marlton, MBBS<sup>8</sup> ; Björn E. Wahlin, MD, PhD<sup>9</sup> ; Ramon Garcia-Sanz, MD, PhD<sup>10</sup> ; Helen McCarthy, MD<sup>11</sup> ; Stephen Mulligan, PhD, MBBS<sup>12</sup> ; Alessandra Tedeschi, MD<sup>13</sup>; Jorge J. Castillo, MD<sup>14</sup> ; Jaroslaw Czyz, MD, PhD<sup>15</sup> ; Carlos Fernández de Larrea, MD, PhD<sup>16</sup> ; David Belada, PhD<sup>17</sup>; Edward Libby, MD<sup>18</sup>; Jeffrey Matous, MD<sup>19</sup>; Marina Motta, MD<sup>20</sup> ; Tanya Siddiqi, MD<sup>21</sup> ; Monica Tani, MD<sup>22</sup>; Marek Trněný, MD<sup>23</sup> ; Monique C. Minnema, MD, PhD<sup>24</sup> ; Christian Buske, MD<sup>25</sup> ; Veronique Leblond, MD, PhD<sup>26</sup>; Steven P. Treon, MD, PhD<sup>14</sup> ; Judith Trotman, MBChB<sup>27</sup> ; Wai Y. Chan, PhD<sup>28</sup>; Jingjing Schneider, PhD<sup>28</sup>; Heather Allewelt, MD<sup>28</sup>; Sheel Patel, PharmD<sup>28</sup> ; Aileen Cohen, MD<sup>28</sup>; and Constantine S. Tam, MD<sup>2,29</sup> 

DOI <https://doi.org/10.1200/JCO.22.02830>

## ABSTRACT

The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. The primary end point was the sum of very good partial response (VGPR) + complete response (CR) rates; secondary and exploratory end points were also reported. Cohort 1 comprised 201 patients (myeloid differentiation primary response 88–mutant WM: 102 receiving zanubrutinib; 99 receiving ibrutinib); cohort 2 comprised 28 patients (myeloid differentiation primary response 88 wild-type WM: 28 zanubrutinib; 26 efficacy evaluable). At 44.4-month median follow-up, VGPR + CR rates were 36.3% with zanubrutinib versus 25.3% with ibrutinib in cohort 1 and 30.8% with one CR in cohort 2. In patients with CXC motif chemokine receptor 4 mutation, VGPR + CR rates were 21.2% with zanubrutinib versus 10.0% with ibrutinib (cohort 1). Median progression-free survival and overall survival were not reached. Any-grade adverse events (AEs) of diarrhea (34.7% v 22.8%), muscle spasms (28.6% v 11.9%), hypertension (25.5% v 14.9%), atrial fibrillation/flutter (23.5% v 7.9%), and pneumonia (18.4% v 5.0%) were more common with ibrutinib versus zanubrutinib; neutropenia (20.4% v 34.7%) was less common with ibrutinib versus zanubrutinib (cohort 1). Zanubrutinib was associated with lower risk of AE-related treatment discontinuation. Overall, these findings confirm the long-term response quality and tolerability associated with zanubrutinib.

## ACCOMPANYING CONTENT

-  [Data Supplement](#)
-  [Protocol](#)

Accepted May 8, 2023

Published July 21, 2023

J Clin Oncol 00:1-8

© 2023 by American Society of  
Clinical Oncology



[View Online  
Article](#)

Licensed under the Creative  
Commons Attribution 4.0 License

## INTRODUCTION

Zanubrutinib is a potent, selective next-generation covalent Bruton tyrosine kinase inhibitor approved in several countries for Waldenström macroglobulinemia (WM) in adults.<sup>1-4</sup> Despite not meeting its primary end point at a median follow-up of 19.4 months in ASPEN, zanubrutinib demonstrated comparable efficacy and favorable safety compared with ibrutinib.<sup>5</sup> With 2 years of additional follow-up in ASPEN, we present long-term efficacy and safety analyses.

## METHODS

The open-label, phase III ASPEN study (ClinicalTrials.gov identifier: [NCT03053440](https://clinicaltrials.gov/ct2/show/study/NCT03053440)) compared ibrutinib versus zanubrutinib in patients with WM. Cohort 1 included patients with mutant myeloid differentiation primary response 88 (*MYD88<sup>MUT</sup>*) randomly assigned 1:1 to zanubrutinib 160 mg

twice daily or ibrutinib 420 mg once daily; cohort 2 included patients with wild-type *MYD88* (*MYD88<sup>WT</sup>*) who received zanubrutinib 160 mg twice a day.<sup>5</sup> Study design, methods, and primary analysis results have been described.<sup>5,6</sup> The ASPEN study was approved by the independent institutional review board or independent ethics committee at each study site and was conducted in accordance with applicable regulatory requirements, the principles of the Declaration of Helsinki, and Good Clinical Practice guidelines of the International Conference on Harmonization. All patients provided written informed consent.

## RESULTS

### Patient Disposition and Characteristics

From January 2017 to July 2018, 201 patients with *MYD88<sup>MUT</sup>* WM were enrolled in cohort 1 (102 receiving

zanubrutinib; 99 receiving ibrutinib); 28 patients were enrolled in cohort 2 (26 *MYD88*<sup>WT</sup>; two unknown). More patients randomly assigned to zanubrutinib than ibrutinib were older than 75 years (33.3% v 22.2%, respectively;  $P = .084$ ) and had CXC motif chemokine receptor 4 mutation (*CXCR4*<sup>MUT</sup>) disease (32.4% v 20.2%, respectively; **Table 1**;  $P = .073$ ). At a median follow-up of 44.4 months (range, 0.4-57.3), 65.7% of patients on zanubrutinib and 51.5% on ibrutinib remained on treatment (cohort 1). At a median follow-up of 42.9 months (range, 2.3-53.7), 35.7%

of patients remained on zanubrutinib (cohort 2; Data Supplement [Fig 1], online only).

## Efficacy

Very good partial response (VGPR) rates increased over time and were numerically higher with zanubrutinib than ibrutinib at all time points (**Fig 1A**). The median time to VGPR was faster for patients on zanubrutinib (6.7 months) versus ibrutinib (16.6 months); the median time to overall (minor response or better) or major (partial response or better) responses were similar between arms. Median durations of response were not reached (**Table 2**).

**TABLE 1. Patient Baseline Characteristics**

Characteristic	Cohort 1		Cohort 2
	Ibrutinib (n = 99)	Zanubrutinib (n = 102)	Zanubrutinib (n = 28)
Age, median (range)	70 (38-90)	70 (45-87)	72 (39-87)
Age 65 years or older, No. (%)	70 (70.7)	61 (59.8)	19 (67.9)
Age 75 years or older, No. (%)	22 (22.2)	34 (33.3)	12 (42.9)
Male sex, No. (%)	65 (65.7)	69 (67.6)	14 (50.0)
Prior lines of therapy, No. (%)			
0	18 (18.2)	19 (18.6)	5 (17.9)
1-3	74 (74.7)	76 (74.5)	20 (71.4)
>3	7 (7.1)	7 (6.9)	3 (10.7)
Genotype by NGS, No. (%)			
<i>CXCR4</i> <sup>WT</sup>	72 (72.7)	65 (63.7)	19 (67.9)
<i>CXCR4</i> <sup>MUT</sup>	20 (20.2)	33 (32.4)	1 (3.6)
<i>CXCR4</i> <sup>FS</sup>	7 (7.1)	19 (18.6)	1 (3.6)
<i>CXCR4</i> <sup>NS</sup>	13 (13.1)	14 (13.7)	0
Unknown <sup>b</sup>	7 (7.1)	4 (3.9)	8 (28.6)
IPSS WM, No. (%)			
Low	13 (13.1)	17 (16.7)	5 (17.9)
Intermediate	42 (42.4)	38 (37.3)	11 (39.3)
High	44 (44.4)	47 (46.1)	12 (42.9)
Hemoglobin $\leq$ 110 g/L, No. (%)	53 (53.5)	67 (65.7)	15 (53.6)
Baseline IgM (g/L, central lab), median (range)	34.2 (2.4-108.0)	31.8 (5.8-86.9)	28.5 (5.6-73.4)
Bone marrow involvement, % median (range)	60 (0-90)	60 (0-90)	22.5 (0-90)
Extramedullary disease, <sup>a</sup> No. (%)	66 (66.7)	63 (61.8)	16 (57.1)

Abbreviations: *CXCR4*<sup>MUT</sup>, CXC motif chemokine receptor 4 mutation; *CXCR4*<sup>WT</sup>, CXC motif chemokine receptor 4 wild-type; FS, frameshift mutation; IgM, immunoglobulin M; IPSS, International Prognostic Scoring System; NGS, next-generation sequencing; NS, nonsense mutation; WM, Waldenström macroglobulinemia.

<sup>a</sup>Assessed by investigator.

<sup>b</sup>Confirmatory genotyping by NGS was performed for ad hoc analyses. Nineteen patients (11 in cohort 1, two in cohort 2) had unknown *CXCR4* mutation status because of withdrawal of consent (one), quality control failure (nine), or sample not collected (nine); two patients in cohort 2 had unknown *MYD88* mutation status because of insufficient sample.

In patients with *CXCR4*<sup>MUT</sup>, higher major response rates and faster median time to response were observed with zanubrutinib versus ibrutinib (**Table 2**). Regardless of *CXCR4* mutational status or mutation type (nonsense v frameshift), VGPR + complete response (CR) rates were numerically higher for zanubrutinib versus ibrutinib.<sup>7</sup> In patients with baseline extramedullary disease, the VGPR + CR rate difference was 18.8% (95% CI, 2.4 to 35.1) favoring zanubrutinib, consistent with the greater median reduction observed in lymphadenopathy (65.9% v 52.5%) and splenomegaly (20.0% v 15.0%) for zanubrutinib versus ibrutinib, respectively. VGPR + CR rates were 36.8% versus 22.2% in patients on zanubrutinib versus ibrutinib, respectively, with zero lines of prior therapy; 36.8% versus 25.7% with one to three lines of prior therapy; 28.6% versus 28.6% with greater than three lines of prior therapy. One CR was reported (cohort 2); the VGPR + CR rate was 30.8% and the major response rate was 65.4% in 26 patients with confirmed *MYD88*<sup>WT</sup> WM.

Fewer progression-free survival (PFS; hazard ratio [HR], 0.63 [95% CI, 0.36 to 1.12]) and overall survival (OS; HR, 0.75 [95% CI, 0.36 to 1.59]) events were observed on zanubrutinib (cohort 1); median PFS or OS were not reached in the intent-to-treat population (**Table 2**; **Figs 1B** and **1C**). In patients with *CXCR4*<sup>MUT</sup> WM on ibrutinib, the median PFS was 39.8 months (Data Supplement [Figs 2 and 3]). In cohort 2, 42-month event-free rates for PFS were lower than cohort 1; OS was comparable between cohorts (87.5% v 83.9%; **Table 2**; Data Supplement [Fig 4]).

## Long-Term Safety


Most common reasons for discontinuing treatment were AEs (cohort 1: nine zanubrutinib, 20 ibrutinib; cohort 2: six) and disease progression (cohort 1: 14 zanubrutinib, 13 ibrutinib; cohort 2: eight; Data Supplement [Fig 1]). Median treatment duration and relative dose intensities were similar between arms (cohort 1).

Any-grade AEs of diarrhea, muscle spasms, hypertension, atrial fibrillation/flutter, and pneumonia were more common with ibrutinib versus zanubrutinib; neutropenia was less common with ibrutinib versus zanubrutinib (cohort 1;

Data Supplement [Tables 1 and 2]). Incidences of AEs observed with zanubrutinib were similar between cohorts (Data Supplement [Table 3]). More patients on ibrutinib experienced cardiovascular AEs, including one incidence of ventricular arrhythmia (Data Supplement [Table 4]).

Except for neutropenia, prevalence of AEs of interest (Data Supplement [Table 5]) were lower with zanubrutinib than ibrutinib at all time points (Fig 1D). Exposure-adjusted

incidences of atrial fibrillation/flutter, hypertension, and diarrhea were significantly lower with zanubrutinib versus ibrutinib, respectively (descriptive  $P < .05$ ; Data Supplement [Fig 5]). With zanubrutinib, the prevalence of neutropenia and infection decreased over time. By >36 months of treatment, the prevalence of infection was lower in patients receiving zanubrutinib than ibrutinib; the prevalence of neutropenia was similar between arms (Fig 1D).



**FIG 1.** (A) Best overall response rates over time as assessed by investigator, (B) progression-free survival, and (C) overall survival in the intent-to-treat patients (99 receiving ibrutinib; 102 receiving zanubrutinib at each time point) and (D) prevalence analysis for adverse events of interest from 0 to >36 months (cohort 1). Data cutoff: October 31, 2021. \*N is the number of patients who are on treatment in each time interval or who discontinued treatment. The time from first dose date to the earliest date (last dose date + 30 days, initiation of new anticancer therapy, end of study, death or cutoff date) is within the time interval. The prevalence of each interval is the No. of patients with a new or ongoing event during the interval, shown as % of N. HR, hazard ratio; MR, minor response; PR, partial response; SD, stable disease; VGPR, very good partial response. (continued on following page)




FIG 1. (Continued).

More patients on ibrutinib than zanubrutinib required dose reductions because of AEs (cohort 1; Data Supplement [Table 3]). Treatment-emergent AEs led to discontinuation in 20 (20.4%) patients on ibrutinib versus nine (8.9%) on zanubrutinib. Most common AEs leading to discontinuation with ibrutinib were cardiac disorders and infections and infestations, with zanubrutinib as second malignancy (Data Supplement [Table 3]). Higher risk of treatment discontinuation because of AEs ( $P < .05$ ) and initiation of next treatment ( $P = .0977$ ) was observed for ibrutinib versus zanubrutinib (Data Supplement [Figs 6 and 7]).

Eight AE-related deaths occurred in cohort 1 (five ibrutinib; three zanubrutinib); three AE-related deaths occurred in cohort 2 (Data Supplement [Table 3]).

## DISCUSSION

In ASPEN, zanubrutinib demonstrated meaningful efficacy by consistently exhibiting high-quality responses and favorable safety across 2 years of additional follow-up. High VGPR + CR rates observed with zanubrutinib across mutational groups also reflect a clinical benefit because achieving immunoglobulin M (IgM) reduction of >90% is associated with less IgM-related morbidity.

**TABLE 2.** Overall and Mutational Efficacy Outcomes as Assessed by Investigator With Zanubrutinib and Ibrutinib in Cohorts 1 and 2

Outcome	Overall—Cohort 1		CXCR4 <sup>MUT</sup> —Cohort 1		CXCR4 <sup>WT</sup> —Cohort 1		MYD88 <sup>WT</sup> —Cohort 2
	Ibrutinib (n = 99)	Zanubrutinib (n = 102)	Ibrutinib (n = 20)	Zanubrutinib (n = 33)	Ibrutinib (n = 72)	Zanubrutinib (n = 65)	Zanubrutinib (n = 26)
Treatment duration, months, median (range)	42.23 (0.3-57.0)	43.37 (0.8-57.2)	39.64 (0.3-50.3)	44.75 (1.7-57.2)	43.40 (0.5-57.0)	42.43 (0.8-54.4)	30.03 (1.4-49.0)
Relative dose intensity, %	96.98	98.20	94.47	97.44	97.58	98.35	96.89
Best overall response, No. (%)							
CR	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.8)
VGPR	25 (25.3)	37 (36.3)	2 (10.0)	7 (21.2)	22 (30.6)	29 (44.6)	7 (26.9)
PR	54 (54.5)	46 (45.1)	11 (55.0)	19 (57.6)	39 (54.2)	25 (38.5)	9 (34.6)
MR	14 (14.1)	14 (13.7)	6 (30.0)	4 (12.1)	7 (9.7)	9 (13.8)	4 (15.4)
SD	3 (3.0)	3 (2.9)	0 (0.0)	3 (9.1)	3 (4.2)	0 (0.0)	4 (15.4)
PD	2 (2.0)	1 (1.0)	1 (5.0)	0 (0.0)	1 (1.4)	1 (1.5)	1 (3.8)
NE <sup>a</sup>	1 (1.0)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)	0 (0.0)
Response rates, % (95% CI)							
VGPR + CR	25.3 (17.1 to 35.0)	36.3 (27.0 to 46.4)	10.0 (1.2 to 31.7)	21.2 (9.0 to 38.9)	30.6 (20.2 to 42.5)	44.6 (32.3 to 57.5)	30.8 (14.3 to 51.8)
<i>P</i>		.07		.35		.10	NA
Major response rate	79.8 (70.5 to 87.2)	81.4 (72.4 to 88.4)	65.0 (40.8 to 84.6)	78.8 (61.1 to 91.0)	84.7 (74.3 to 92.1)	83.1 (71.7 to 91.2)	65.4 (44.3 to 82.8)
ORR	93.9 (87.3 to 97.7)	95.1 (88.9 to 98.4)	95.0 (75.1 to 99.9)	90.9 (75.7 to 98.1)	94.4 (86.4 to 98.5)	96.9 (89.3 to 99.6)	80.8 (60.6 to 93.4)
Time to response, months							
Median time to VGPR + CR	16.59	6.67	31.31	11.10	11.33	6.51	6.88
Median time to major response	2.92	2.83	6.64	3.37	2.83	2.79	2.96
Median time to OR	0.99	1.02	1.25	1.08	0.99	1.02	0.99
Duration of VGPR + CR, months							
Median DOR (range) <sup>b</sup>	NE (0.0+ to 43.0+)	NE (2.9+ to 47.9+)	23.2 (1.0+ to 23.2)	NE (14.1 to 43.3+)	NE (0.0+ to 43.0+)	NE (2.9+ to 47.9+)	NE (13.8 to 44.1+)
24-month event-free rate, % (95% CI)	79.3 (53.5 to 91.8)	90.6 (73.6 to 96.9)	0.0 (NE to NE)	85.7 (33.4 to 97.9)	83.9 (57.9 to 94.5)	91.8 (71.1 to 97.9)	60.0 (19.5 to 85.2)
42-month event-free rate, % (95% CI)	72.7 (45.7 to 87.9)	81.7 (60.9 to 92.1)	0.0 (NE to NE)	64.3 (15.1 to 90.2)	76.9 (49.0 to 90.8)	86.1 (62.1 to 95.4)	60.0 (19.5 to 85.2)
Duration of major response, months							
Median DOR (range)	NE (0.0+ to 53.2+)	NE (0.0+ to 51.5+)	38.6 (1.9+ to 47.0+)	NE (0.0+ to 50.8+)	NE (0.0+ to 53.2+)	NE (2.7 to 51.5+)	23.7 (0.0+ to 44.1+)
42-month event-free rate, % (95% CI)	74.9 (62.4 to 83.7)	80.7 (69.5 to 88.1)	38.9 (7.2 to 71.2)	70.4 (45.2 to 85.7)	78.6 (65.4 to 87.3)	85.8 (72.4 to 93.0)	42.2 (18.1 to 64.6)
PFS							
Events, No. (%)	30 (30.3)	20 (19.6)	11 (55.0)	8 (24.2)	18 (25.0)	11 (16.9)	13 (50.0)
HR (95% CI)	0.63 (0.36 to 1.12)		0.5 (0.20 to 1.29)		0.70 (0.33 to 1.50)		—
<i>P</i>		.12		.15		.36	—
Median (range)	NE (0.0+ to 55.4+)	NE (0.0+ to 55.1+)	39.8 (0.4 to 49.8+)	NE (2.0+ to 55.1+)	NE (0.1 to 55.4+)	NE (0.0+ to 52.6+)	45.8 (1.6 to 47.0+)
42-month event-free rate, % (95% CI)	69.7 (58.9 to 78.2)	78.3 (68.4 to 85.5)	49.0 (24.5 to 69.7)	73.2 (53.3 to 85.6)	74.6 (62.3 to 83.4)	81.3 (68.7 to 89.2)	53.8 (33.3 to 70.6)

(continued on following page)

**TABLE 2.** Overall and Mutational Efficacy Outcomes as Assessed by Investigator With Zanubrutinib and Ibrutinib in Cohorts 1 and 2 (continued)

Outcome	Overall—Cohort 1		<i>CXCR4</i> <sup>MUT</sup> —Cohort 1		<i>CXCR4</i> <sup>WT</sup> —Cohort 1		<i>MYD88</i> <sup>WT</sup> —Cohort 2
	Ibrutinib (n = 99)	Zanubrutinib (n = 102)	Ibrutinib (n = 20)	Zanubrutinib (n = 33)	Ibrutinib (n = 72)	Zanubrutinib (n = 65)	Zanubrutinib (n = 26)
OS							
Events	17 (17.2)	12 (11.8)	6 (30.0)	5 (15.2)	11 (15.3)	7 (10.8)	5 (19.2)
HR (95% CI)	0.75 (0.36 to 1.59)		0.54 (0.16 to 1.81)		0.82 (0.32 to 2.13)		—
<i>P</i>	.45		.32		.69		—
Median (range)	NE (0.5 to 57.1+)	NE (0.4+ to 57.3+)	48.2 (0.5 to 50.4+)	NE (4.0+ to 57.3+)	NE (1.3 to 57.1+)	NE (0.4+ to 54.4+)	NE (2.3 to 53.7+)
42-month event-free rate, % (95% CI)	85.2 (76.3 to 91.0)	87.5 (79.0 to 92.7)	78.8 (52.7 to 91.5)	84.2 (66.0 to 93.1)	85.6 (74.8 to 92.0)	88.5 (77.4 to 94.4)	83.9 (62.6 to 93.7)

Abbreviations: +, censored; CR, complete response; *CXCR4*<sup>MUT</sup>, CXC motif chemokine receptor 4 mutation; *CXCR4*<sup>WT</sup>, CXC motif chemokine receptor 4 wild-type; DOR, duration of response; HR, hazard ratio; MR, minor response; *MYD88*<sup>WT</sup>, myeloid differentiation primary response 88 wild-type; NA, not available; NE, not evaluable; OR, overall response; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; VGPR, very good partial response.

<sup>a</sup>Discontinued before first assessment.

<sup>b</sup>Median follow-up time estimated by reverse Kaplan-Meier method for VGPR + CR responses were 27, 36, NE, 40, 28, 34, and 30 months, respectively.

In other studies, no patients with *MYD88*<sup>WT</sup> WM achieved a major response with ibrutinib or a VGPR/CR with acalabrutinib.<sup>8,9</sup> In the ASPEN study, 31% of patients with *MYD88*<sup>WT</sup> WM achieved a VGPR/CR with zanubrutinib, including one CR, after 44-month follow-up. Furthermore, PFS and OS in patients with *MYD88*<sup>WT</sup> WM in our study were compared favorably with those receiving ibrutinib ± rituximab treatment in other studies, although all were limited by small sample size, and cross trial comparison was not possible.<sup>10,11</sup> Our findings support zanubrutinib as the preferred treatment for patients with *MYD88*<sup>WT</sup> WM.

Zanubrutinib exhibited fewer side effects associated with off-target binding, especially cardiovascular toxicities. With zanubrutinib, no cases of ventricular arrhythmia were observed; neutropenia occurred early and was neither treatment-limiting nor associated with a higher infection rate. Zanubrutinib was associated with longer treatment duration and lower risk of dose reduction or discontinuation because of AEs.<sup>12</sup> Patients previously intolerant to ibrutinib or acalabrutinib did not experience a recurrence of treatment-related AEs with zanubrutinib.<sup>12</sup>

## AFFILIATIONS

<sup>1</sup>National and Kapodistrian University of Athens, Athens, Greece

<sup>2</sup>Monash Health & Monash University, Clayton, VIC, Australia

<sup>3</sup>Centre for Waldenström's Macroglobulinemia & Associated Disorders, University College London Hospital Foundation Trust, London, United Kingdom

<sup>4</sup>Maria Skłodowska-Curie National Institute of Oncology, Krakow, Poland

<sup>5</sup>Flinders Medical Centre, Adelaide, SA, Australia

<sup>6</sup>Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, Australia

<sup>7</sup>St James University Hospital, Leeds, United Kingdom

<sup>8</sup>Princess Alexandra Hospital and University of Queensland, Brisbane, QLD, Australia

<sup>9</sup>Karolinska Universitetssjukhuset & Karolinska Institutet, Stockholm, Sweden

<sup>10</sup>Hospital Universitario de Salamanca, Salamanca, Spain

<sup>11</sup>Royal Bournemouth & Christchurch Hospital, Bournemouth, United Kingdom

<sup>12</sup>Royal North Shore Hospital, Sydney, NSW, Australia

<sup>13</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

<sup>14</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>15</sup>Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland

<sup>16</sup>Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain

<sup>17</sup>FN Hradec Králové, Hradec Králové, Czechia

<sup>18</sup>Fred Hutchinson Cancer Center, Seattle, WA

<sup>19</sup>Colorado Blood Cancer Institute, Denver, CO

<sup>20</sup>AO Spedali Civili di Brescia, Lombardia, Italy

<sup>21</sup>City of Hope National Medical Center, Duarte, CA

<sup>22</sup>Ospedale Civile Santa Maria delle Croci, AUSL Ravenna, Ravenna, Italy

<sup>23</sup>Všeobecná fakultní nemocnice v Praze, Prague, Czechia

<sup>24</sup>University Medical Center Utrecht, Utrecht, The Netherlands

<sup>25</sup>Institute of Experimental Cancer Research –CCC Ulm– Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany

<sup>26</sup>Sorbonne University, Pitié Salpêtrière Hospital, Paris, France

<sup>27</sup>Concord Repatriation General Hospital, Sydney, NSW, Australia

Study limitations include an open-label design, unknown *CXCR4* mutational status, and more patients with *CXCR4* mutations randomly assigned to zanubrutinib versus ibrutinib (cohort 1), all of which may have influenced the VGPR + CR rates observed. VGPR + CR rate was chosen as the primary end point for this study because of the prolonged responses and infrequent PFS/OS events expected and because response rates and depth of response are associated with PFS and time to next treatment in patients with WM.<sup>13–15</sup> Although potential false negatives may have occurred because of assay sensitivity or lower bone marrow disease involvement in patients with *MYD88*<sup>WT</sup> WM, the assay was sufficient for detection congruent with expected mutation rates.<sup>16</sup> Potential associations between *CXCR4* nonsense versus frameshift mutations and treatment outcomes were evaluated (manuscript in preparation).

Extended follow-up results confirm improved long-term safety and tolerability of zanubrutinib compared with ibrutinib and support deeper, earlier, and more durable responses in patients with WM regardless of previous treatment or *CXCR4* and *MYD88* mutational statuses.

<sup>28</sup>BeiGene USA, Inc, San Mateo, CA

<sup>29</sup>The Alfred Hospital, Melbourne, VIC, Australia

## CORRESPONDING AUTHOR

Meletios A. Dimopoulos, MD, School of Medicine, National and Kapodistrian University of Athens, 80 Vasilissis Sofias Ave, Athens 11528, Greece; Twitter: @thanosdimop; e-mail: mdimop@med.uoa.gr.

## PRIOR PRESENTATION

Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2022; the European Hematology Association Congress, Vienna, Austria, June 9-12, 2022; the Pan Pacific Lymphoma Conference, Koloa, HI, July 18-22, 2022; and the International Workshop on Waldenström Macroglobulinemia, Madrid, Spain, October 27-30, 2022.

## SUPPORT

BeiGene sponsored the study. Investigators and BeiGene collaborated on protocol development, data collection, and interpretation. BeiGene performed statistical analyses.

## CLINICAL TRIAL INFORMATION

[NCT03053440](https://clinicaltrials.gov/ct2/show/study/NCT03053440)

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.22.02830>.

## DATA SHARING STATEMENT

The redacted study Protocol is provided online only with this article. All authors had access to the original data for the analyses described here. On request and subject to certain criteria, conditions, and exceptions, BeiGene will provide access to individual deidentified participant data

from BeiGene-sponsored global interventional clinical studies conducted for medicines (1) for indications that have been approved or (2) in programs that have been terminated. Data requests may be submitted to [DataDisclosure@beigene.com](mailto:DataDisclosure@beigene.com).

## AUTHOR CONTRIBUTIONS

**Conception and design:** Stephen Opat, Roger G. Owen, Alessandra Tedeschi, Christian Buske, Veronique Leblond, Aileen Cohen, Constantine S. Tam

**Provision of study materials or patients:** Meletios A. Dimopoulos, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramon Garcia-Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trěný, Monique C. Minnema, Christian Buske, Veronique

Leblond, Steven P. Treon, Judith Trotman, Constantine S. Tam  
**Collection and assembly of data:** Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Sheel Patel, Aileen Cohen  
**Data analysis and interpretation:** All authors  
**Manuscript writing:** All authors  
**Final approval of manuscript:** All authors  
**Accountable for all aspects of the work:** All authors

## ACKNOWLEDGMENT

We thank study patients, their supporters, and investigators and clinical research staff at study centers. Medical writing and editorial assistance were provided, under the direction of the authors, by Laura S. Moye, PhD and Elizabeth G. Wheatley, PhD of Bio Connections, LLC, (Chicago, IL) supported by BeiGene.

## REFERENCES

- Guo Y, Liu Y, Hu N, et al: Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase. *J Med Chem* 62:7923-7940, 2019
- BRUKINSA [package insert]. San Mateo, CA. BeiGene USA, Inc, 2021
- BRUKINSA [product monograph]. BeiGene Switzerland GmbH. 2021
- National Medical Products Administration: Approved drug data search. <https://www.nmpa.gov.cn/datasearch/>
- Tam CS, Opat S, D'Sa S, et al: A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: The ASPEN study. *Blood* 136:2038-2050, 2020
- Dimopoulos M, Sanz RG, Lee H-P, et al: Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial. *Blood Adv* 4:6009-6018, 2020
- Dimopoulos M, Opat S, D'Sa S, et al: ASPEN biomarker analysis: Response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia harboring CXCR4, TP53, and TERT mutations. 11th International Workshop on Waldenström's Macroglobulinemia. Madrid, Spain, 2022, pp WM041
- Treon SP, Tripsas CK, Meid K, et al: Ibrutinib in previously treated Waldenstrom's macroglobulinemia. *N Engl J Med* 372:1430-1440, 2015
- Owen RG, McCarthy H, Rule S, et al: Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: A single-arm, multicentre, phase 2 study. *Lancet Haematol* 7:e112-e121, 2020
- Treon SP, Meid K, Gustine J, et al: Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom macroglobulinemia. *J Clin Oncol* 39:565-575, 2021
- Buske C, Tedeschi A, Trotman J, et al: Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom's macroglobulinemia: Final analysis from the randomized phase III INNOVATE study. *J Clin Oncol* 40:52-62, 2022
- Shadman M, Flinn IW, Levy MY, et al: A phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant of prior Bruton Tyrosine Kinase inhibitors. *Lancet Haematol* 10:e35-e45, 2023
- Kapoor P, Treon SP: The race to stymie BTK: Zanu zings. *Blood* 136:1997-1999, 2020
- Castillo JJ, Abeykoon JP, Gustine JN, et al: Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. *Br J Haematol* 192:542-550, 2021
- Paludo J, Abeykoon JP, Gertz MA, et al: Depth of response in Waldenstrom macroglobulinemia. *Blood* 132, 2018 (suppl 1; abstr 4141)
- Treon SP, Cao Y, Xu L, et al: Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. *Blood* 123:2791-2796, 2014

**AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST****Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/authors/author-center](http://ascopubs.org/jco/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://Open Payments)).

**Meletios A. Dimopoulos**

**Honoraria:** Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, BeiGene, Sanofi

**Consulting or Advisory Role:** Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, BeiGene, Sanofi

**Stephen Opat**

**Honoraria:** AbbVie, AstraZeneca, Janssen, Roche, Gilead Sciences, Mundipharma, Takeda, Merck, BeiGene

**Consulting or Advisory Role:** AbbVie, AstraZeneca, Janssen, Celgene, Novartis, Gilead Sciences, Takeda, Merck, Mundipharma, CSL Behring

**Research Funding:** AstraZeneca (Inst), BeiGene (Inst), Roche (Inst), AbbVie (Inst), Gilead Sciences (Inst), Takeda (Inst), Pharmacyclics (Inst), Janssen (Inst), Celgene (Inst), Merck (Inst), Epizyme (Inst)

**Travel, Accommodations, Expenses:** EUSA Pharma

**Shirley D'Sa**

**Honoraria:** BeiGene (Inst)

**Consulting or Advisory Role:** BeiGene, Sanofi (Inst), Kite, a Gilead company (Inst)

**Speakers' Bureau:** BeiGene (Inst)

**Research Funding:** BeiGene (Inst)

**Travel, Accommodations, Expenses:** BeiGene

**Wojciech Jurczak**

**Consulting or Advisory Role:** BeiGene, AstraZeneca, Lilly

**Research Funding:** Roche, Takeda, Janssen-Cilag, BeiGene, Morphosys, AstraZeneca, Lilly

**Hui-Peng Lee**

**Stock and Other Ownership Interests:** CSL Behring

**Honoraria:** Takeda

**Consulting or Advisory Role:** BeiGene

**Uncompensated Relationships:** HSANZ

**Gavin Cull**

**Research Funding:** BeiGene (Inst), AstraZeneca (Inst), Glyomimetics (Inst)

**Roger G. Owen**

**Honoraria:** Janssen-Cilag, BeiGene, AstraZeneca

**Consulting or Advisory Role:** BeiGene, Janssen-Cilag

**Travel, Accommodations, Expenses:** BeiGene

**Paula Marlton**

**Consulting or Advisory Role:** Novartis, AbbVie, Astellas Pharma, Pfizer, BeiGene, Jazz Pharmaceuticals, Gilead Sciences, AstraZeneca, Janssen, Menarini, MSD, Otsuka, Servier

**Speakers' Bureau:** AbbVie

**Björn E. Wahlin**

**Stock and Other Ownership Interests:** Genmab

**Research Funding:** Roche

**Ramon Garcia-Sanz**

**Honoraria:** Janssen, Takeda, Amgen, BeiGene, Novartis, AstraZeneca Spain

**Consulting or Advisory Role:** Janssen

**Research Funding:** Incyte (Inst), Astellas Pharma, Takeda (Inst), Takeda (Inst)

**Patents, Royalties, Other Intellectual Property:** BIOMED 2 primers (Inst)

**Travel, Accommodations, Expenses:** Janssen, Takeda

**Other Relationship:** Spanish Society of Hematology

**Helen McCarthy**

**Honoraria:** Janssen/Pharmacyclics

**Consulting or Advisory Role:** BeiGene

**Travel, Accommodations, Expenses:** BeiGene

**Stephen Mulligan**

**Honoraria:** Janssen, BeiGene

**Consulting or Advisory Role:** Janssen, BeiGene

**Speakers' Bureau:** Janssen

**Alessandra Tedeschi**

**Consulting or Advisory Role:** Janssen, BeiGene, AstraZeneca, AbbVie

**Speakers' Bureau:** AbbVie, AstraZeneca, Janssen, BeiGene

**Jorge J. Castillo**

**Consulting or Advisory Role:** Janssen, Roche/Genentech, BeiGene, AbbVie/Pharmacyclics, Cellectar, Loxo/Lilly, Kite/Gilead

**Research Funding:** Pharmacyclics (Inst), AbbVie (Inst), BeiGene (Inst), TG Therapeutics (Inst), AstraZeneca (Inst), Cellectar (Inst), Loxo/Lilly (Inst)

**Carlos Fernández de Larrea**

**Honoraria:** Janssen, BeiGene, Bristol Myers Squibb/Celgene, Pfizer, Amgen

**Consulting or Advisory Role:** Janssen, Bristol Myers Squibb/Celgene, Amgen, Pfizer, Sanofi, BeiGene

**Research Funding:** Janssen (Inst), Bristol Myers Squibb/Celgene (Inst), Amgen (Inst)

**Travel, Accommodations, Expenses:** Janssen, Amgen, GlaxoSmithKline, Bristol Myers Squibb/Celgene

**David Belada**

**Consulting or Advisory Role:** Roche, Gilead Sciences, Janssen-Cilag, Takeda, MorphoSys, BeiGene, Genmab, AstraZeneca, Pharmacyclics

**Research Funding:** Roche (Inst), Gilead Sciences (Inst), Janssen-Cilag (Inst), Takeda (Inst), MorphoSys (Inst), Pharmacyclics (Inst), Dr Reddy's (Inst), Genmab (Inst)

**Travel, Accommodations, Expenses:** Gilead Sciences, Takeda, Roche

**Edward Libby****Honoraria:** Curio Science, Pharmacyclics**Consulting or Advisory Role:** Pharmacyclics/Janssen**Research Funding:** GlaxoSmithKline (Inst), Janssen (Inst), Genentech (Inst), BeiGene (Inst)**Jeffrey Matous****Consulting or Advisory Role:** Pharmacyclics, BeiGene**Tanya Siddiqi****Consulting or Advisory Role:** AstraZeneca, BeiGene, Celgene, Bristol Myers Squibb/Celgene, AbbVie, Kite, a Gilead company**Speakers' Bureau:** AstraZeneca, BeiGene, Bristol Myers Squibb/Celgene**Research Funding:** Juno Therapeutics (Inst), Kite, a Gilead company (Inst), Acerta Pharma (Inst), TG Therapeutics (Inst), BeiGene (Inst), Pharmacyclics (Inst), Celgene (Inst), Oncernal Therapeutics (Inst), Bristol Myers Squibb/Sanofi (Inst), Ascentage Pharma (Inst), AstraZeneca (Inst)**Monica Tani****Consulting or Advisory Role:** Incyte, AbbVie, Kirin Pharmaceuticals**Marek Trněný****Honoraria:** Janssen, Gilead Sciences, Takeda, Bristol Myers Squibb, Amgen, AbbVie, Roche, MorphoSys, Novartis**Consulting or Advisory Role:** Takeda, Bristol Myers Squibb, Incyte, AbbVie, Amgen, Roche, Gilead Sciences, Janssen, MorphoSys, Novartis, Genmab, Sobi**Travel, Accommodations, Expenses:** Gilead Sciences, Takeda, Bristol Myers Squibb, Roche, Janssen, AbbVie**Monique C. Minnema****Consulting or Advisory Role:** Janssen-Cilag (Inst), CDR-life (Inst), GlaxoSmithKline (Inst)**Speakers' Bureau:** Celgene/Bristol Myers Squibb (Inst), Medscape (Inst), Janssen Medical Affairs (Inst)**Research Funding:** BeiGene (Inst)**Christian Buske****Honoraria:** Roche/Genentech, Janssen, BeiGene, Novartis, Pfizer, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron, Hexal, Bayer, Sobi**Consulting or Advisory Role:** Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Regeneron, MorphoSys, Novartis, Bayer**Speakers' Bureau:** Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences, Bayer, Hexal, MorphoSys, Regeneron, Novartis, Sobi**Research Funding:** Roche/Genentech, Janssen, Celltrion, MSD, Amgen, Bayer (Inst)**Veronique Leblond****Honoraria:** AstraZeneca, BeiGene, Amgen, Janssen Oncology, AbbVie, MSD Oncology, Lilly**Consulting or Advisory Role:** BeiGene, Janssen, AstraZeneca, Lilly, AbbVie**Speakers' Bureau:** BeiGene, AstraZeneca, AbbVie**Travel, Accommodations, Expenses:** AbbVie**Steven P. Treon****Honoraria:** AbbVie/Pharmacyclics, Janssen Oncology, BeiGene**Consulting or Advisory Role:** Janssen, Pharmacyclics, BeiGene**Research Funding:** Pharmacyclics, X4 Pharma (Inst), Lilly (Inst), BeiGene (Inst), AbbVie (Inst)**Patents, Royalties, Other Intellectual Property:** My institution holds patents related to use of MYD88 and CXCR4 testing for which a predetermined financial distribution to the laboratory and individuals is provided. I have not received any income to this date related to these patents (Inst)**Judith Trotman****Research Funding:** BeiGene (Inst), Roche/Genentech (Inst), Pharmacyclics (Inst), Janssen-Cilag (Inst), Takeda (Inst), BMS (Inst), Cellectar (Inst)**Travel, Accommodations, Expenses:** Roche/Genentech**Wai Y. Chan****Employment:** BeiGene USA**Stock and Other Ownership Interests:** BeiGene, Bristol Myers Squibb**Jingjing Schneider****Employment:** BeiGene**Stock and Other Ownership Interests:** BeiGene**Travel, Accommodations, Expenses:** BeiGene**Heather Allewelt****Employment:** BeiGene, Nkarta**Leadership:** Nkarta**Stock and Other Ownership Interests:** BeiGene, Nkarta**Research Funding:** BeiGene, Nkarta**Patents, Royalties, Other Intellectual Property:** My husband is a named inventor on a patent held by St Jude Children's Research Hospital regarding the use of expanded NK cells in the treatment of cancer**Travel, Accommodations, Expenses:** BeiGene, Nkarta**Sheel Patel****Employment:** BeiGene**Stock and Other Ownership Interests:** BeiGene**Travel, Accommodations, Expenses:** BeiGene**Aileen Cohen****Employment:** BeiGene**Stock and Other Ownership Interests:** BeiGene**Constantine S. Tam****Honoraria:** Janssen-Cilag, AbbVie, Novartis, BeiGene, Pharmacyclics, Roche/Genentech, Loxo/Lilly**Consulting or Advisory Role:** Janssen, Loxo, Roche, BeiGene, AbbVie**Research Funding:** Janssen-Cilag (Inst), AbbVie (Inst), BeiGene (Inst)

No other potential conflicts of interest were reported.